Brokerages Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) PT at $6.29

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have been assigned an average recommendation of “Moderate Buy” from the eight analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $6.29.

A number of brokerages have recently issued reports on FULC. Cantor Fitzgerald upgraded shares of Fulcrum Therapeutics from a “neutral” rating to an “overweight” rating and set a $10.00 target price on the stock in a research report on Thursday, May 15th. Leerink Partners raised Fulcrum Therapeutics from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $4.00 to $12.00 in a report on Friday, May 23rd. HC Wainwright reiterated a “neutral” rating and issued a $4.00 price objective on shares of Fulcrum Therapeutics in a research report on Wednesday, February 26th. Piper Sandler restated an “overweight” rating and set a $9.00 target price (up previously from $6.00) on shares of Fulcrum Therapeutics in a research report on Thursday, May 29th. Finally, Leerink Partnrs raised Fulcrum Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 23rd.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of FULC. BNP Paribas Financial Markets acquired a new position in shares of Fulcrum Therapeutics during the 4th quarter worth about $38,000. Jump Financial LLC acquired a new position in Fulcrum Therapeutics during the first quarter valued at approximately $30,000. Brooklyn Investment Group boosted its position in Fulcrum Therapeutics by 209.7% during the first quarter. Brooklyn Investment Group now owns 12,190 shares of the company’s stock valued at $35,000 after purchasing an additional 8,254 shares during the last quarter. Virtu Financial LLC bought a new position in Fulcrum Therapeutics in the first quarter valued at approximately $39,000. Finally, Mariner LLC acquired a new position in shares of Fulcrum Therapeutics during the 4th quarter worth approximately $78,000. 89.83% of the stock is currently owned by institutional investors.

Fulcrum Therapeutics Stock Performance

FULC opened at $6.90 on Friday. The firm has a market cap of $372.46 million, a price-to-earnings ratio of -22.26 and a beta of 2.41. The firm’s 50-day simple moving average is $4.98 and its 200-day simple moving average is $4.21. Fulcrum Therapeutics has a twelve month low of $2.32 and a twelve month high of $10.13.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.01. As a group, sell-side analysts anticipate that Fulcrum Therapeutics will post -0.16 EPS for the current fiscal year.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.